E2-EPF5, a novel therapeutic protein and target

Details for Australian Patent Application No. 2005295863 (hide)

Owner Novartis AG

Inventors Labow, Mark Aron; Hall, Jonathan; Schmid, Peter; Mickanin, Craig Stephen; Wyder, Lorenza; Asselbergs, Fred A.; Huesken, Dieter; Weiler, Jan

Agent Davies Collison Cave

Pub. Number AU-A-2005295863

PCT Pub. Number WO2006/044366

Priority 60/618,907 14.10.04 US

Filing date 12 October 2005

Wipo publication date 27 April 2006

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/044366 Priority application(s): WO2006/044366

17 June 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005295864-Surgical navigation systems and processes for unicompartmental knee arthroplasty

2005295860-1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mGluR3 receptor antagonists